Need help finding what you are looking for?
Contact Us
PUBLISHER: Allied Market Research | PRODUCT CODE: 1070539
PUBLISHER: Allied Market Research | PRODUCT CODE: 1070539
Nanomedicine Market by Modality, Application, and Indication: Global Opportunity Analysis and Industry Forecast, 2021-2030
PUBLISHED:
PAGES: 215 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global nanomedicine market was valued at $171,695.33 million in 2020, and is projected to reach $393,046.52 million by 2030, registering a CAGR of 9.2% from 2021 to 2030.
Nanomedicine is a branch of medicine that uses tools and knowledge of nanotechnology for prevention and treatment of different diseases. Nanomedicines are multifunctional drugs with programmable properties that find applications in monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. They have the potential to revolutionize the current scenario of detection of disease, its treatment, and diagnosis methods.
Emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, and rise in government support and funding drive growth of the market. Moreover, growth in need for safe and cost-effective therapies also contribute toward growth of the market. However, long approval process and risks associated with nanomedicines (environmental impact) are expected to hinder the market growth. Conversely, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are expected to offer lucrative opportunities for market expansion during the forecast period.
The nanomedicine market is segmented on the basis of modality, application, indication and region. On the basis of modality, the market is segmented into diagnostics and treatment. On the basis of application, the market is segmented into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. On the basis of indication, the market is segmented into clinical oncology, infectious diseases, clinical cardiology, orthopedics, neurology, urology, ophthalmology, immunology and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the nanomedicine market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
- By MODALITY
- Diagnostics
- Treatment
- By APPLICATION
- Drug Delivery
- Diagnostic Imaging
- Vaccines
- Regenerative Medicine
- Implants
- Others
- By INDICATION
- Clinical Oncology
- Infectious Diseases
- Clinical Cardiology
- Orthopedics
- Neurology
- Urology
- Ophthalmology
- Immunology
- Others
- By REGION
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- North America
KEY MARKET PLAYERS
- Abbott Laboratories
- DiaSorin S.p.A.
- General Electric Company
- Invitae Corporation
- Johnson & Johnson
- Leadient BioSciences Inc.
- Mallinckrodt plc
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceuticals Ltd.
Product Code: LI_172021 / A01691
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report Description
- 1.2.Key Market Segments
- 1.3.Key Benefits
- 1.4.Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE
- 3.1.Market Definition and Scope
- 3.2.Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3.Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4.Market Share Analysis/Top Player Positioning
- 3.4.1. Market Share Analysis/Top Player Positioning 2020
- 3.5.Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities
- 3.6.COVID-19 Impact Analysis
CHAPTER 4:NANOMEDICINE MARKET, BY APPLICATION
- 4.1.Market Overview
- 4.1.1Market Size and Forecast, By Application
- 4.2. Drug Delivery
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Diagnostic Imaging
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Regenerative Medicine
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- 4.5. Implants
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
- 4.6. Vaccines
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
- 4.7. Others
- 4.7.1. Key Market Trends, Growth Factors and Opportunities
- 4.7.2. Market Size and Forecast, By Region
- 4.7.3. Market Share Analysis, By Country
CHAPTER 5:NANOMEDICINE MARKET, BY INDICATION
- 5.1.Market Overview
- 5.1.1Market Size and Forecast, By Indication
- 5.2. Clinical Oncology
- 5.2.1. Market Size and Forecast, By Region
- 5.2.2. Market Share Analysis, By Country
- 5.3. Infectious Diseases
- 5.3.1. Market Size and Forecast, By Region
- 5.3.2. Market Share Analysis, By Country
- 5.4. Clinical Cardiology
- 5.4.1. Market Size and Forecast, By Region
- 5.4.2. Market Share Analysis, By Country
- 5.5. Orthopedics
- 5.5.1. Market Size and Forecast, By Region
- 5.5.2. Market Share Analysis, By Country
- 5.6. Neurology
- 5.6.1. Market Size and Forecast, By Region
- 5.6.2. Market Share Analysis, By Country
- 5.7. Urology
- 5.7.1. Market Size and Forecast, By Region
- 5.7.2. Market Share Analysis, By Country
- 5.8. Ophthalmology
- 5.8.1. Market Size and Forecast, By Region
- 5.8.2. Market Share Analysis, By Country
- 5.9. Immunology
- 5.9.1. Market Size and Forecast, By Region
- 5.9.2. Market Share Analysis, By Country
- 5.10. Others
- 5.10.1. Market Size and Forecast, By Region
- 5.10.2. Market Share Analysis, By Country
CHAPTER 6:NANOMEDICINE MARKET, BY MODALITY
- 6.1.Market Overview
- 6.1.1.Market Size and Forecast, By Modality
- 6.2. Treatments
- 6.2.1. Market Size and Forecast, By Region
- 6.2.2. Market Share Analysis, By Country
- 6.3. Diagnostics
- 6.3.1. Market Size and Forecast, By Region
- 6.3.2. Market Share Analysis, By Country
CHAPTER 7:NANOMEDICINE MARKET, BY REGION
- 7.1.Market Overview
- 7.1.1Market Size and Forecast, By Region
- 7.2.North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Application
- 7.2.3. Market Size and Forecast, By Indication
- 7.2.4. Market Size and Forecast, By Modality
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. United States Nanomedicine Market
- 7.2.6.1. Market Size and Forecast, By Application
- 7.2.6.2. Market Size and Forecast, By Indication
- 7.2.6.3. Market Size and Forecast, By Modality
- 7.2.7. Canada Nanomedicine Market
- 7.2.7.1. Market Size and Forecast, By Application
- 7.2.7.2. Market Size and Forecast, By Indication
- 7.2.7.3. Market Size and Forecast, By Modality
- 7.2.8. Mexico Nanomedicine Market
- 7.2.8.1. Market Size and Forecast, By Application
- 7.2.8.2. Market Size and Forecast, By Indication
- 7.2.8.3. Market Size and Forecast, By Modality
- 7.3.Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Application
- 7.3.3. Market Size and Forecast, By Indication
- 7.3.4. Market Size and Forecast, By Modality
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Nanomedicine Market
- 7.3.6.1. Market Size and Forecast, By Application
- 7.3.6.2. Market Size and Forecast, By Indication
- 7.3.6.3. Market Size and Forecast, By Modality
- 7.3.7. France Nanomedicine Market
- 7.3.7.1. Market Size and Forecast, By Application
- 7.3.7.2. Market Size and Forecast, By Indication
- 7.3.7.3. Market Size and Forecast, By Modality
- 7.3.8. Uk Nanomedicine Market
- 7.3.8.1. Market Size and Forecast, By Application
- 7.3.8.2. Market Size and Forecast, By Indication
- 7.3.8.3. Market Size and Forecast, By Modality
- 7.3.9. Italy Nanomedicine Market
- 7.3.9.1. Market Size and Forecast, By Application
- 7.3.9.2. Market Size and Forecast, By Indication
- 7.3.9.3. Market Size and Forecast, By Modality
- 7.3.10. Spain Nanomedicine Market
- 7.3.10.1. Market Size and Forecast, By Application
- 7.3.10.2. Market Size and Forecast, By Indication
- 7.3.10.3. Market Size and Forecast, By Modality
- 7.3.11. Rest Of Europe Nanomedicine Market
- 7.3.11.1. Market Size and Forecast, By Application
- 7.3.11.2. Market Size and Forecast, By Indication
- 7.3.11.3. Market Size and Forecast, By Modality
- 7.4.Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Application
- 7.4.3. Market Size and Forecast, By Indication
- 7.4.4. Market Size and Forecast, By Modality
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Nanomedicine Market
- 7.4.6.1. Market Size and Forecast, By Application
- 7.4.6.2. Market Size and Forecast, By Indication
- 7.4.6.3. Market Size and Forecast, By Modality
- 7.4.7. China Nanomedicine Market
- 7.4.7.1. Market Size and Forecast, By Application
- 7.4.7.2. Market Size and Forecast, By Indication
- 7.4.7.3. Market Size and Forecast, By Modality
- 7.4.8. Australia Nanomedicine Market
- 7.4.8.1. Market Size and Forecast, By Application
- 7.4.8.2. Market Size and Forecast, By Indication
- 7.4.8.3. Market Size and Forecast, By Modality
- 7.4.9. India Nanomedicine Market
- 7.4.9.1. Market Size and Forecast, By Application
- 7.4.9.2. Market Size and Forecast, By Indication
- 7.4.9.3. Market Size and Forecast, By Modality
- 7.4.10. South Korea Nanomedicine Market
- 7.4.10.1. Market Size and Forecast, By Application
- 7.4.10.2. Market Size and Forecast, By Indication
- 7.4.10.3. Market Size and Forecast, By Modality
- 7.4.11. Rest Of Asia-pacific Nanomedicine Market
- 7.4.11.1. Market Size and Forecast, By Application
- 7.4.11.2. Market Size and Forecast, By Indication
- 7.4.11.3. Market Size and Forecast, By Modality
- 7.5.LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Application
- 7.5.3. Market Size and Forecast, By Indication
- 7.5.4. Market Size and Forecast, By Modality
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Nanomedicine Market
- 7.5.6.1. Market Size and Forecast, By Application
- 7.5.6.2. Market Size and Forecast, By Indication
- 7.5.6.3. Market Size and Forecast, By Modality
- 7.5.7. Saudi Arabia Nanomedicine Market
- 7.5.7.1. Market Size and Forecast, By Application
- 7.5.7.2. Market Size and Forecast, By Indication
- 7.5.7.3. Market Size and Forecast, By Modality
- 7.5.8. South Africa Nanomedicine Market
- 7.5.8.1. Market Size and Forecast, By Application
- 7.5.8.2. Market Size and Forecast, By Indication
- 7.5.8.3. Market Size and Forecast, By Modality
- 7.5.9. Rest of LAMEA Nanomedicine Market
- 7.5.9.1. Market Size and Forecast, By Application
- 7.5.9.2. Market Size and Forecast, By Indication
- 7.5.9.3. Market Size and Forecast, By Modality
CHAPTER 8:COMPANY PROFILES
- 8.1. Abbott Laboratories
- 8.1.1.Company Overview
- 8.1.2.Key Executives
- 8.1.3.Company snapshot
- 8.1.4.Operating business segments
- 8.1.5.Product portfolio
- 8.1.6.Business Performance
- 8.1.7.Key Strategic Moves and Developments
- 8.2. DiaSorin S.p.A.
- 8.2.1.Company Overview
- 8.2.2.Key Executives
- 8.2.3.Company snapshot
- 8.2.4.Operating business segments
- 8.2.5.Product portfolio
- 8.2.6.Business Performance
- 8.2.7.Key Strategic Moves and Developments
- 8.3. General Electric Company
- 8.3.1.Company Overview
- 8.3.2.Key Executives
- 8.3.3.Company snapshot
- 8.3.4.Operating business segments
- 8.3.5.Product portfolio
- 8.3.6.Business Performance
- 8.3.7.Key Strategic Moves and Developments
- 8.4. Invitae Corporation
- 8.4.1.Company Overview
- 8.4.2.Key Executives
- 8.4.3.Company snapshot
- 8.4.4.Operating business segments
- 8.4.5.Product portfolio
- 8.4.6.Business Performance
- 8.4.7.Key Strategic Moves and Developments
- 8.5. JOHNSON & JOHNSON
- 8.5.1.Company Overview
- 8.5.2.Key Executives
- 8.5.3.Company snapshot
- 8.5.4.Operating business segments
- 8.5.5.Product portfolio
- 8.5.6.Business Performance
- 8.5.7.Key Strategic Moves and Developments
- 8.6. Leadiant Biosciences, Inc.
- 8.6.1.Company Overview
- 8.6.2.Key Executives
- 8.6.3.Company snapshot
- 8.6.4.Operating business segments
- 8.6.5.Product portfolio
- 8.6.6.Business Performance
- 8.6.7.Key Strategic Moves and Developments
- 8.7. Mallinckrodt Plc
- 8.7.1.Company Overview
- 8.7.2.Key Executives
- 8.7.3.Company snapshot
- 8.7.4.Operating business segments
- 8.7.5.Product portfolio
- 8.7.6.Business Performance
- 8.7.7.Key Strategic Moves and Developments
- 8.8. MERCK & CO., INC.
- 8.8.1.Company Overview
- 8.8.2.Key Executives
- 8.8.3.Company snapshot
- 8.8.4.Operating business segments
- 8.8.5.Product portfolio
- 8.8.6.Business Performance
- 8.8.7.Key Strategic Moves and Developments
- 8.9. PFIZER, INC.
- 8.9.1.Company Overview
- 8.9.2.Key Executives
- 8.9.3.Company snapshot
- 8.9.4.Operating business segments
- 8.9.5.Product portfolio
- 8.9.6.Business Performance
- 8.9.7.Key Strategic Moves and Developments
- 8.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- 8.10.1.Company Overview
- 8.10.2.Key Executives
- 8.10.3.Company snapshot
- 8.10.4.Operating business segments
- 8.10.5.Product portfolio
- 8.10.6.Business Performance
- 8.10.7.Key Strategic Moves and Developments
Product Code: LI_172021 / A01691
LIST OF TABLES
- TABLE 1.GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 2.GLOBAL NANOMEDICINE MARKET FOR DRUG DELIVERY, BY REGION, 2020-2030 ($MILLION)
- TABLE 3.GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2020-2030 ($MILLION)
- TABLE 4.GLOBAL NANOMEDICINE MARKET FOR REGENERATIVE MEDICINE, BY REGION, 2020-2030 ($MILLION)
- TABLE 5.GLOBAL NANOMEDICINE MARKET FOR IMPLANTS, BY REGION, 2020-2030 ($MILLION)
- TABLE 6.GLOBAL NANOMEDICINE MARKET FOR VACCINES, BY REGION, 2020-2030 ($MILLION)
- TABLE 7.GLOBAL NANOMEDICINE MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
- TABLE 8.GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 9.GLOBAL NANOMEDICINE MARKET FOR CLINICAL ONCOLOGY, BY REGION, 2020-2030 ($MILLION)
- TABLE 10.GLOBAL NANOMEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2030 ($MILLION)
- TABLE 11.GLOBAL NANOMEDICINE MARKET FOR CLINICAL CARDIOLOGY, BY REGION, 2020-2030 ($MILLION)
- TABLE 12.GLOBAL NANOMEDICINE MARKET FOR ORTHOPEDICS, BY REGION, 2020-2030 ($MILLION)
- TABLE 13.GLOBAL NANOMEDICINE MARKET FOR NEUROLOGY, BY REGION, 2020-2030 ($MILLION)
- TABLE 14.GLOBAL NANOMEDICINE MARKET FOR UROLOGY, BY REGION, 2020-2030 ($MILLION)
- TABLE 15.GLOBAL NANOMEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2020-2030 ($MILLION)
- TABLE 16.GLOBAL NANOMEDICINE MARKET FOR IMMUNOLOGY, BY REGION, 2020-2030 ($MILLION)
- TABLE 17.GLOBAL NANOMEDICINE MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
- TABLE 18.GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 19.GLOBAL NANOMEDICINE MARKET FOR TREATMENTS, BY REGION, 2020-2030 ($MILLION)
- TABLE 20.GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTICS, BY REGION, 2020-2030 ($MILLION)
- TABLE 21.GLOBAL NANOMEDICINE MARKET, BY REGION, 2020-2030 ($MILLION)
- TABLE 22.NORTH AMERICA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 23.NORTH AMERICA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 24.NORTH AMERICA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 25.UNITED STATES NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 26.UNITED STATES NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 27.UNITED STATES NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 28.CANADA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 29.CANADA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 30.CANADA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 31.MEXICO NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 32.MEXICO NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 33.MEXICO NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 34.EUROPE NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 35.EUROPE NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 36.EUROPE NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 37.GERMANY NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 38.GERMANY NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 39.GERMANY NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 40.FRANCE NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 41.FRANCE NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 42.FRANCE NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 43.UK NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 44.UK NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 45.UK NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 46.ITALY NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 47.ITALY NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 48.ITALY NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 49.SPAIN NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 50.SPAIN NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 51.SPAIN NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 52.REST OF EUROPE NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 53.REST OF EUROPE NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 54.REST OF EUROPE NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 55.ASIA-PACIFIC NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 56.ASIA-PACIFIC NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 57.ASIA-PACIFIC NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 58.JAPAN NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 59.JAPAN NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 60.JAPAN NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 61.CHINA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 62.CHINA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 63.CHINA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 64.AUSTRALIA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 65.AUSTRALIA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 66.AUSTRALIA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 67.INDIA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 68.INDIA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 69.INDIA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 70.SOUTH KOREA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 71.SOUTH KOREA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 72.SOUTH KOREA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 73.REST OF ASIA-PACIFIC NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 74.REST OF ASIA-PACIFIC NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 75.REST OF ASIA-PACIFIC NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 76.LAMEA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 77.LAMEA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 78.LAMEA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 79.BRAZIL NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 80.BRAZIL NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 81.BRAZIL NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 82.SAUDI ARABIA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 83.SAUDI ARABIA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 84.SAUDI ARABIA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 85.SOUTH AFRICA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 86.SOUTH AFRICA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 87.SOUTH AFRICA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 88.REST OF LAMEA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 89.REST OF LAMEA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 90.REST OF LAMEA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)
- TABLE 91.ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 92.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 93.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 94.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 95.ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 96.DIASORIN S.P.A.: KEY EXECUTIVES
- TABLE 97.DIASORIN S.P.A.: COMPANY SNAPSHOT
- TABLE 98.DIASORIN S.P.A.: OPERATING SEGMENTS
- TABLE 99.DIASORIN S.P.A.: PRODUCT PORTFOLIO
- TABLE 100.DIASORIN S.P.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 101.GENERAL ELECTRIC COMPANY: KEY EXECUTIVES
- TABLE 102.GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT
- TABLE 103.GENERAL ELECTRIC COMPANY: OPERATING SEGMENTS
- TABLE 104.GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO
- TABLE 105.GENERAL ELECTRIC COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 106.INVITAE CORPORATION: KEY EXECUTIVES
- TABLE 107.INVITAE CORPORATION: COMPANY SNAPSHOT
- TABLE 108.INVITAE CORPORATION: OPERATING SEGMENTS
- TABLE 109.INVITAE CORPORATION: PRODUCT PORTFOLIO
- TABLE 110.INVITAE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 111.JOHNSON & JOHNSON: KEY EXECUTIVES
- TABLE 112.JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 113.JOHNSON & JOHNSON: OPERATING SEGMENTS
- TABLE 114.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 115.JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 116.LEADIANT BIOSCIENCES, INC.: KEY EXECUTIVES
- TABLE 117.LEADIANT BIOSCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 118.LEADIANT BIOSCIENCES, INC.: OPERATING SEGMENTS
- TABLE 119.LEADIANT BIOSCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 120.LEADIANT BIOSCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 121.MALLINCKRODT PLC: KEY EXECUTIVES
- TABLE 122.MALLINCKRODT PLC: COMPANY SNAPSHOT
- TABLE 123.MALLINCKRODT PLC: OPERATING SEGMENTS
- TABLE 124.MALLINCKRODT PLC: PRODUCT PORTFOLIO
- TABLE 125.MALLINCKRODT PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 126.MERCK & CO., INC.: KEY EXECUTIVES
- TABLE 127.MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 128.MERCK & CO., INC.: OPERATING SEGMENTS
- TABLE 129.MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 130.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 131.PFIZER, INC.: KEY EXECUTIVES
- TABLE 132.PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 133.PFIZER, INC.: OPERATING SEGMENTS
- TABLE 134.PFIZER, INC.: PRODUCT PORTFOLIO
- TABLE 135.PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 136.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
- TABLE 137.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 138.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
- TABLE 139.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- TABLE 140.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
- FIGURE 1.GLOBAL NANOMEDICINE MARKET SEGMENTATION
- FIGURE 2.GLOBAL NANOMEDICINE MARKET
- FIGURE 3.SEGMENTATION NANOMEDICINE MARKET
- FIGURE 4.TOP INVESTMENT POCKET IN NANOMEDICINE MARKET
- FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
- FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
- FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
- FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
- FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
- FIGURE 11.LOW THREAT OF SUBSTITUTION
- FIGURE 12.HIGH COMPETITIVE RIVALRY
- FIGURE 13.TOP PLAYER POSITIONING, 2020
- FIGURE 14.MARKET SHARE ANALYSIS, 2020
- FIGURE 15.RESTRAINTS AND DRIVERS: NANOMEDICINE MARKET
- FIGURE 16.NANOMEDICINE MARKET SEGMENTATION, BY APPLICATION
- FIGURE 17.NANOMEDICINE MARKET FOR DRUG DELIVERY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 18.NANOMEDICINE MARKET FOR DIAGNOSTIC IMAGING, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 19.NANOMEDICINE MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 20.NANOMEDICINE MARKET FOR IMPLANTS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 21.NANOMEDICINE MARKET FOR VACCINES, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 22.NANOMEDICINE MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 23.NANOMEDICINE MARKET SEGMENTATION, BY INDICATION
- FIGURE 24.NANOMEDICINE MARKET FOR CLINICAL ONCOLOGY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 25.NANOMEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 26.NANOMEDICINE MARKET FOR CLINICAL CARDIOLOGY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 27.NANOMEDICINE MARKET FOR ORTHOPEDICS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 28.NANOMEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 29.NANOMEDICINE MARKET FOR UROLOGY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 30.NANOMEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 31.NANOMEDICINE MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 32.NANOMEDICINE MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 33.NANOMEDICINE MARKET SEGMENTATION, BY MODALITY
- FIGURE 34.NANOMEDICINE MARKET FOR TREATMENTS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 35.NANOMEDICINE MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 36.ABBOTT LABORATORIES: NET SALES, 2018-2020 ($MILLION)
- FIGURE 37.ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 38.ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 39.DIASORIN S.P.A.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 40.DIASORIN S.P.A.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 41.DIASORIN S.P.A.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 42.GENERAL ELECTRIC COMPANY: NET SALES, 2018-2020 ($MILLION)
- FIGURE 43.GENERAL ELECTRIC COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 44.GENERAL ELECTRIC COMPANY: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 45.INVITAE CORPORATION: NET SALES, 2018-2020 ($MILLION)
- FIGURE 46.INVITAE CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 47.INVITAE CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 48.JOHNSON & JOHNSON: NET SALES, 2018-2020 ($MILLION)
- FIGURE 49.JOHNSON & JOHNSON: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 50.JOHNSON & JOHNSON: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 51.LEADIANT BIOSCIENCES, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 52.LEADIANT BIOSCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 53.LEADIANT BIOSCIENCES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 54.MALLINCKRODT PLC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 55.MALLINCKRODT PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 56.MALLINCKRODT PLC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 57.MERCK & CO., INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 58.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 59.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 60.PFIZER, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 61.PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 62.PFIZER, INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 63.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, 2018-2020 ($MILLION)
- FIGURE 64.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 65.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.